Syndicated Post-ASH 2014 MDoutlook® OncoPolls™: Insight Into the Global Hematological Oncology Disease Landscape: CLL, ALL, Multiple Myeloma

Introduction

In an effort to provide you with timely physician feedback from ASH 2014, OBR and MDoutlook are pleased to share results from MDoutlook OncoPoll surveys fielded immediately after the meeting. This report explores the impact of new data in CLL, ALL, and Multiple Myeloma presented at ASH 2014, held in San Francisco, California, December 6 – 9, 2014.

2014 Post-ASH OncoPoll: Chronic Lymphocytic Leukemia (CLL)

MDoutlook OncoPoll Methodology

  • Primary research phase involved a global survey to MDoutlook’s proprietary U.S. and European panel of verified and validated hematological oncologists screened for patient volume in CLL
  • Timing: December 2014. Launched three days after close of ASH 2014
  • Reponses at data collection: 150 respondents – representing 18 countries

o 43 US respondents

o 20 German respondents

o 17 French respondents

o 21 Italian respondents

o 19 Spanish respondents

o 30 Rest of Europe (ROE) respondents

CLL Patient Volume in Past 3 Months

Assessment of the Clinical Importance & Concept of Anti-CD20 Antibodies Maintenance Therapy for CLL Patients

Key Conclusions

  • Countries with the highest regard that anti-CD20 antibodies used in 1st line will become standard clinical practice in CLL MT: Germany (44%), Spain (42%), and France (41%)
  • Countries with the highest regard that MT with anti-CD20 antibodies will not become standard practice: U.S. (43%), France (41%), and Germany (33%)
  • Countries with the highest regard that using a different anti-CD20 antibody from that used in 1st line will become standard clinical practice in CLL MT: Italy (44%), Spain (32%) and ROE (28%)

Impact of Presentations on Tyrosine Kinase Inhibitors Ibrutinib and Idelalisib for the Treatment of CLL

Key Conclusion

  • 90%-100% of all respondents rated the clinical importance of the information in this abstract 4 or 5 (on 5pt scale)

Key Conclusion

  • 80%-100% of all respondents rated the clinical importance of the information in this abstract 4 or 5 (on 5pt scale)

2014 ASH OncoPoll: Acute Lymphocytic Leukemia (ALL)

MDoutlook OncoPoll Methodology

  • Primary research phase involved a global survey to MDoutlook proprietary U.S. panel of hematological oncologists screened to verify they managed at least 1 ALL patient aged ≥16 years old in the last 12 months
  • Timing: December 2014. Launched three days after close of ASH 2014
  • Reponses at data collection: 77 US respondents

Survey Participants’ Practice Setting and ASH Meeting Attendance

Respondent Characteristics and ALL Patient Volume

Key Conclusion

  • Respondents averaged 20 ALL patients in last 12 months

BLAST Study (Phase 2): Evaluation of Blinatumomab (MT103) for the Treatment of ALL Patients with Minimal Residual Disease

Key Conclusions

  • Based upon Phase 2 BLAST study results, physicians project they will place 23% of their 1st line and 51% of their 2nd line relapsed or refractory B-Cell precursor patients on blinatumomab
  • By 3rd and 4th line, physicians project they will place ~60% of their relapsed or refractory B-Cell precursor patients on blinatumomab

2014 ASH OncoPoll: Multiple Myeloma (MM)

MDoutlook OncoPoll Methodology

  • Primary research phase involved a global survey to MDoutlook panel of hematological oncologists screened for patient volume in multiple myeloma
  • Timing: December 2014. Launched three days after close of ASH 2014
  • Reponses at data collection: 127 respondents representing 35 countries

o 43 US respondents

o 40 EU5 respondents

o 27 Rest of Europe (ROE) respondents

o 17 Rest of World (ROW) respondents

Respondent Practice Classification and Meeting Attendance

Key Conclusions

  • The majority of US respondents practice in a community setting (69%) and did not attend ASH (60%)
  • A slight majority of ex-US respondents practice in an academic setting (54%) and did not attend ASH (52%)

Multiple Myeloma Patient Volume

Key Conclusions

  • US respondents have seen, on average 39 relapsed/refractory MM patients, which is 56% of their patient volume
  • Ex-US respondents have seen an even distribution (~33%) of newly diagnosed transplant eligible, ineligible, and relapsed/refractory MM patients

ASPIRE Trial (Phase 3): Evaluation of Carfilzomib, Lenalidomide, and Dexamethasone vs. Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

Key Conclusions

  • Proportion of U.S. patients treated with KRd is projected to increase >2x over the next 6 months (from 16% to 38% of patients), while the proportion of patients treated with Rd will decrease 7%
  • Proportion of Ex-U.S. patients treated with KRd is projected to increase from 4% to 14% of patients over the next 6 months, while the proportion of patients treated with Rd will decrease 5%

STRATUS Trial (Phase 3): Evaluation of Pomalidomide in Combination with Dexamethasone (Low Dose) in Patients with Refractory or Relapsed Multiple Myeloma

Key Conclusions

  • Proportion of U.S. patients treated with POM + LoDex is projected to increase 7% over the next 6 months
  • Proportion of Ex-U.S. patients treated with POM + LoDex is projected to double over the next 6 months (from 14% to 28% of patients)

To download a copy of this analysis report or to get more information on the full ASH2014 analysis report that expands on these topics and delivers much more – including the impact of additional ASH data announcements on physician awareness, their clinical assessment of the potential impact of these therapies & projected future clinical utilization, please click here.

Submitted by Raj Manimaran, Global Medical Analyst; Jessica Harnisch, Assoc. Global Medical Analyst; Robert Stephan, Sr. Director Medical Services and Strategy; Craig Krugman, Sr. Vice President; and Jan Heybroek, President.

    • 43 US respondents
    • 40 EU5 respondents
    • 27 Rest of Europe (ROE) respondents
    • 17 Rest of World (ROW) respondents
    • 35 countries represented

article register

Recent Posts

Recent Comments

Archives

Categories

Post a Comment

You must be logged in to post a comment